CANbridge Pharmaceuticals Inc. (HKEX:1228) is a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies for rare disease. CANbridge has a differentiated drug portfolio, with 3 approved drugs and a pipeline of 8 assets, targeting prevalent rare disease indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria and other complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases. The CANbridge Next-Generation Innovation and Process Development Facility is developing novel, potentially curative, gene therapies for rare genetic diseases, including Pompe disease, Fabry disease,, Duchenne muscular dystrophy (DMD) and other neuromuscular conditions, and collaborates with world-leading researchers and biotech companies. CANbridge global partners include: Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, UMass Chan Medical School, and Scriptr Global.
We are led by a management team with significant industry experience in rare diseases, spanning R&D, clinical development, regulatory affairs, business development and commercialization.As of now, 42% of our employees have a Ph.D. and/or M.D. degree. And more than 70% of our employees have prior experience working at multinational biopharmaceutical companies. Our management team has a track record of successfully achieving approval and commercializing of rare disease therapies across the key markets, including China, the United States. We leverage this expertise to play an active role in advancing the rare disease industry and shaping the rare disease ecosystem in China.
For example, our founder, Dr. James Qun Xue (“Dr. Xue”), Ph. D., is currently serving as the Deputy Director General of China’s Alliance for Rare Disease (CHARD).
Key pipelines and their milestones:
Livmarli® (maralixibat oral solution, formerly known as CAN108), an oral, minimally absorbed, reversible inhibitor of the ileal bile acid transporter (IBAT) that is under development to treat rare cholestatic liver diseases including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC)
In 2023, CANbridge received multiple marketing approvals for Livmarli in mainland China, Hong Kong, and Taiwan. These approvals make Livmarli the first and only approved product marketed for the treatment of cholestatic pruritus in patients with ALGS in these regions.
Hunterase® (idursulfase beta, formerly known as CAN101), an enzyme replacement therapy (ERT) for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome
In September 2020, we received marketing approval for Hunterase (CAN101) for MPS II in mainland China.
CAN106 (omoprubart), a novel, long-acting monoclonal antibody for the treatment of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH), myasthenia gravis (MG) and other diseases that may benefit from treatment with an anti-C5 antibody
In June 2023, CANbridge Reported positive preliminary top-line data from the ongoing Phase 1b study of CAN106 being conducted in PNH patients in China.
In February 2022, a Phase I single ascending dose study of CAN106 in Singapore recorded positive topline results with complete complement blockade.
CAN103, an ERT for the treatment of Gaucher Disease (GD)
In January 2023, the first patient was dosed in phase 2 trial for the treatment of GD in China.In October Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for GD in China.In July 2024,Last Patient Last Visit in CAN103 Phase 2/Registration Trial for GD.
In August 2024,Positive Topline Data from CAN103 Pivotal Trial for GD in China, Plans NDA Filing in Q4 2024.
In November 13, 2024，CAN103 New Drug Application (NDA), for Gaucher disease, Accepted by China’s National Medical Products Administration.
In March 13, 2025,CAN103(Velaglucerase-beta) for Injection Successfully Passed the Pre-approval inspection and Pre - marketing GMP Compliance Inpection for the Pilot Biological Product of Divided manufacturing.
Gene therapy
In addition to biologics and small molecules, we are investing in next-generation technology for gene therapies. Gene therapies provide a potentially one-time durable treatment for rare genetic diseases that have limited treatment options. As of December 31, 2022, we are developing gene therapies for the treatments of Fabry disease and Pompe disease, which we licensed from LogicBio Therapeutics. In addition, we are internally developing an adeno-associated virus (AAV) delivery platform targeting different tissues, such as the central nervous system (CNS) and muscle.
CANbridge established.
Acquires license for Apogenix's CAN008 for the treatment of glioblastoma in China
Receives approval for CAN008 GBM Phase I/II trial in Taiwan
Doses first patient in CAN008 GBM Phase I/II trial in Taiwan
Submits IND application for CAN008 GBM Phase II/III trial in China
Completes patient enrollment for CAN008 GBM Phase I trial in Taiwan
Receives approval to commence CAN008 GBM Phase II/III trial in China
Enters strategic partnership with WuXi Biologics for rare disease therapeutics development
Submits NDA for CAN101 (Hunterase®) for Hunter syndrome in China
Granted priority review for CAN101 (Hunterase®) in China
Enters research agreement with UMass Medical School for rare disease gene therapy
Enters into second research agreement with Umass Medical school for rare disease gene therapy
First CANbridge rare disease treatment marketing approval in China:
Hunterase®, the first enzyme replacement therapy for Hunter syndrome in the region
CANbridge Pharma announces strategic collaboration with LogicBio Therapeutics, securing licenses to gene delivery and editing platforms
Mirum Pharma and CANbridge Pharma enter into exclusive licensing agreement to develop and commercialize Maralixibat in Greater China for rare liver disease
Obtains CDE clearance from NMPA for an updated Phase II clinical first line trial application for CAN008 in China
Completes $98 million series D and $58 million series E financing
Begins commercialization of Hunterase® (CAN101) in mainland China
Reported Positive Top-Line CAN106 Phase 1 Data
First Patient Dosed in CAN106 Phase 1b/2 Trial for Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
LIVMARLI® New Drug Application/Orphan Drug Registration (NDA/ORD) for Alagille Syndrome Accepted by the Taiwan Food and Drug Administration
CANbridge-UMass Chan Medical School Gene Therapy Research Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
LIVMARLI® New Drug Application (NDA), for Alagille Syndrome, Accepted by China’s National Medical Products Administration
Forms Scientific Advisory Board to Guide Global Development of CAN106 in Complement-mediated Diseases
First Patient Dosed in LIVMARLI® (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for the Treatment of Gaucher Disease in China
CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual Congress
Orphan Drug Designation Granted to CAN 106 for the Treatment of Myasthenia Gravis
First Patient Dosed in CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China
CANbridge and UMass Chan Medical School reported at the 26th ASGCT Annual Meeting that Spinal Muscular Atrophy gene therapy (CAN203) extends life and improves motor function in mice via intracerebroventricular injection
Livmarli® was approved for marketing in mainland China
Positive preliminary data were obtained from the Phase 1b clinical trial of omoprubart (CAN106) injection for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in China
Livmarli® was approved for marketing in Hong Kong
Livmarli® was approved for marketing in Taiwan
CAN103 for the treatment of Gaucher disease completed patient enrollment in the core part of the Phase 2 clinical trial in China
Abstract of gene therapy for Fabry disease presented at the 30th Annual Meeting of the European Society for Gene and Cell Therapy
CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China’s National Medical Products Administration
Foundation consolidated over time and for a rosy future | 2023 China Conference on Rare Diseases closed successfully
Livmarli mentioned as a case study The Policy Address highlights Hong Kong's strengths in research and development, emphasizing its capcity to independently approve new drugs Rare disease drugs will receive significant benefits
CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2023
CANbridge Announces Expansion of LIVMARLI® Label to Include Patients as Young as 3 Months in China
CANbridge Announces Last Patient Last Visit in CAN103 Phase 2/Registration Trial for Gaucher Disease
CANbridge’s Livmarli Is Recommended in The “ Expert Consensus on Diagnosis and Treatment of ALGS Associated Liver Disease” Published By The Chinese Journal of Pediatrics
CANbridge Reports Positive Topline Data from CAN103 Pivotal Trial for Gaucher Disease in China, Plans NDA Filing in Q4 2024
CANbridge Pharmaceuticals’ CAN103 for Gaucher Disease Granted Priority Review Status by CDE of the NMPA
CANbridge Pharmaceuticals Successfully Obtains Drug Manufacturing License Type B Certificate
CANbridge Pharmaceuticals CAN103 New Drug Application (NDA), for Gaucher disease, Accepted by China’s National Medical Products Administration
CANbridge and Scriptr Global Announce Publication in the Journal Science Reporting the Discovery of the StitchR™ RNA Assembly Technology and its Application for the Treatment of Muscular Dystrophies
Dr. James Qun Xue, Ph.D., M.B.A., has served as Chairman of the Board,Director and Chief Executive Officer since the inception of our Company in January 2018 and was re-designated as an executive Director on June 21, 2021. Dr. Xue is the founder of our Company and has been actively involved in the business, strategy and operational management of our Group since its establishment. Dr. Xue has over 22 years of experience in medical and pharmaceutical companies. Dr.Xue began his career as a scientist at Kosan Biosciences, Inc. from May 1998 to August 2000,where he dedicated himself to research in bioengineering. In 2002, Dr. Xue joined GenzymeCorporation, where he served in various positions with increasing responsibilities including,among others, the general manager of Genzyme China and senior director of business excellence, and accumulated extensive management experience there until 2011. Since June 2012, Dr. Xue has served as venture partner at Tullis Health Investors where he was principally responsible for providing advice on portfolio company investments and maintaining and enhancing company’s brand and market position.
Dr. Xue is deputy director general of the China Alliance for Rare Disease (中國罕見病聯盟), deputy director of the Shanghai Foundation for Rare Disease. He is the vice chair of the R&D committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA)，member of the Special Committee on Drugs for Rare Diseases，Chinese Pharmaceutical Association（CPA） and a member of the Leadership Council of the Joint Institute of Peking University Health Science Center and University of Michigan Medical School . Dr. Xue has also been a member of BayHelix Group, a non-profit organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry and a mentor of the Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines.
Dr. Xue obtained his Bachelor of Science degree in pharmaceutical chemistry from Peking University School of Pharmacy in July 1992. He further obtained his Ph.D. in bioorganic chemistry from Brown University in April 1997. In addition, Dr. Xue received his postdoctoral degree in pharmaceutical chemistry and biochemistry from University of California in April 1998 and his Master of Business Administration from Darden School of Business, University of Virginia in May 2002.
Prior to his work with CANbridge, Dr. Cox was Chief Medical Officer for Editas Medicine, in Cambridge, MA. Dr. Cox also had a long stint at Sanofi Genzyme, also in Cambridge, culminating as Vice President, Rare Disease Clinical Development, where he oversaw multiple global rare disease clinical development programs, including Cerdelga®; olipudase alfa; Hectoral®; Cerezyme®, Aldurazyme®, and Elaprase® in Asia, among others. Before then, Dr. Cox held several senior medical R&D positions at Genzyme and was the company’s first clinical geneticist recruited to oversee human clinical development programs for rare genetic diseases.
Dr. Cox is a board-certified clinical geneticist and pediatrician who trained at Boston Children’s Hospital, where he remains on staff and continues to see patients with genetic diseases. He earned an MD and PhD in Biology from the University of California at San Diego, and a Bachelor of Arts in Biology, from Harvard College. He holds multiple patents and awards and has authored scores of peer-reviewed publications, presentations, and book chapters.
Chris Chen has over 23 years of bio-pharmaceutical experience in HR management in multiple roles, including 11 years of professional experience in Human Resource Management at Sinovac Biotech Ltd. (Nasdaq GSM: SVA), during which time the staff size increased from 25 to more than 600 and Sinovac grew from one single company to a group with several subsidiary and JV companies. Immediately prior to coming to CANbridge, Ms. Chen was the HR Director of Huadu Biotech Ltd.
Ms. Chen has a master’s degree in Human Resource Management from RenMin University of China.
Ms. Gao Suya will take over full responsibilities of China commercial operations, organization and P&L, including sales, channel management, marketing, market access, sales force effectiveness (SFE).
Suya joined CANbridge as Director of Major Project Application & Head of HQ Preparation in April 2021. Over the past three years, Suya built a robust relationship with Suzhou Industry Park (SIP) and Suzhou Municipality, successfully led and executed multiple corporate initiatives and achieved substantial outcomes.
Before joining CANbridge, Suya has worked in two pharmaceutical companies for 13 years in Nanjing. From 2008 to 2018, she served as the director of the General Manager's Office of the Sanhome Pharmaceutical Co., Ltd. From 2019 to 2021 she served as Director of Administrative Personnel at Zhongshan Pharmaceutical. She has led the team to complete the application of national major projects and the landmark construction project of traditional Chinese medicine and health industry. Suya has 5 years’ commercial experience in her past working experience.
Suya has a Bachelor of Law degree from Nanjing University and a master of MBA from Nanjing University of Finance and Economics.
Dr. Jeff Kou is the Head of Program Management & Clinical Operations. Dr. Kou has been dedicated on CMC development, portfolio and project management, and alliance management for more than 11 years. The full lifecycle management experience and achievements enable his integrated understanding in biologicals R&D from PCC to IND and NDA, including CMC, non-clinical and clinical development.
Dr. Kou holds PhD degree in Biochemical Engineering from East China University of Science and Technology, and EMBA from Shanghai Advanced Institute of Finance, Shanghai JiaoTong University.
Bettie Li is our Head of Finance Operation and Controller. Prior joining to us, Ms. Li worked at Ernst & Young Hua Ming LLP for 13 years as a senior audit manager, where she assisted local and foreign-invested enterprises in the IPO financing, mergers and acquisitions, annual audit and other businesses.
Ms. Li received her bachelor's degree with a major in Information Management and Information System from Fudan University. She is also a Certified Public Accountant (Member of CICPA and Australia CPA).
Dr. EJ Ma is the Vice President of Business Development and External Innovation. He is responsible for global business development, R&D collaborations and alliance management. Dr. Ma brings 20 years of scientific research, BD, business strategy, and investment experiences to the company. Prior to joining CANbridge, he was an Engagement Manager at Trinity Life Sciences, a global strategy consulting firm, leading teams to provide consulting services to the biotech and pharma industry including serving multiple Fortune 500 pharma clients. Before that, he worked as an investment associate at a biotech investment fund in Boston. He was also a founding member of a precision medicine startup.
Dr. Ma earned his PhD in Immunology and Virology from the University of Illinois and received his postdoctoral training in Cancer Genomics at the Harvard Medical School and business training from the Harvard Business School.
Qian Ma is our head of legal and compliance and serves as one of our joint company secretaries and the board secretary. Prior to joining us, Ms. Ma worked at King & Wood Mallesons where she facilitated our legal and compliance affairs as a designated external counsel. Ms. Ma has professional legal experiences in advising corporate general matters, investments and deals in medical and pharmaceutical industry.
Ms. Ma received her Juris Master degree and her bachelor’s degree in history and international studies from Peking University.
Mr. Shen has considerable experience working in pharmaceutical manufacturing operations, quality, project management and plant operation management over a stellar career spanning more than 30 years. He held technical and managerial positions with increasing responsibilities at global pharmaceutical companies including Fresenius-Kabi Sino-Swed Pharmaceutical Company Ltd., Guangdong Otsuka and Suzhou Otsuka, Eisai(China) and Chinese domestic pharmaceutic companies including CTTQ (江苏正大天晴药业集团), Nanjing Sanhome Pharmaceutical Company and Kintor Pharma. Over the last eight years, he held key executive level leadership roles with responsibilities in production, quality, project management and plant management & operations. He has developed substantial cross-cultural management experience.
Mr. Shen has very rich professional knowledge and practical experience in the production, quality, equipment, validation and process of drugs, especially sterile products. He is familiar with major GMP regulations governed by major regulatory authorities including FDA, EMA and NMPA, and has extensive hands-on experience with GMP inspection and audit of different countries, and also has many successful cases during his career. He was one of the main drafters and revisers of China's 2010 version GMP, the main editor of the "Guidelines for the Implementation of Pharmaceutical GMP"-"Sterile Drugs", and assisted in revising the "Quality Management System", "Utilities and Facilities" and other guidelines, also being one expert reviewing members of "Pre-approval Inspection for Drug Registration" published by Peking university. Over one hundred of public lectures and training were conducted for CFDA, local provinces & cities, and various industry forums. He has also played important roles in different professional associations in China, like CPAPE（中国医药设备工程协会）, CQAP（中国医药质量管理协会），Our Yao(蒲公英) etc.
Mr. Shen graduated from Chinese Pharmaceutical University with a Pharmacy major and then earned his MBA master certificate in Southeast University.
Mr. Will Wang obtained his Bachelor's Degree with major in Pharmacy from Tianjin University in 2005. Prior to joining CANbridge, he worked in Beijing Inno Pharmaceutical Technology Co., Ltd as Plant Manager for 2.5 years. Also, he had served in Ocumension and Suzhou Abogen Biosciences as Production Director with rich experience in Production Management.
Dr. West is a stem cell biology research leader with a depth of industry experience in gene therapy development, platform innovation and clinical candidate development. Most recently, he was at Fractyl Health, Inc., as Senior Director and, previously, Gene Therapy Research Director, were he led in-vivo gene therapy research programs, helped to establish a gene therapy technology platform and pipeline and identify novel AAV capsid delivery procedures. Before then, Dr. West was Senior Scientist and group leader in the Hematology/Advanced Editing Research Department at CRISPR Therapeutics AG, where he applied CRISPR technologies for DNA repair. At CRISPR, Dr. West also identified and established academic and industry partnerships and supported pre-clinical gene editing studies. Prior to CRISPR, Dr. West held research positions at Biogen Inc. and Amgen Inc. Dr. West was a Postdoctoral Research Fellow in the Department of Molecular Biology at Massachusetts General Hospital and a Doctoral candidate at Children’s Hospital Boston. He has a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University, in Cambridge, MA and a Bachelor of Science from West Virginia University, in Morgantown, WV. Dr. West has been published in peer-reviewed publications 17 times and holds three patents.
Ms. Shirley Yue has joined CANbridge in August 2021. Ms.Yue is responsible for the function of Procurement & Supply Chain.
Before joining our company, Ms. Yue served as purchasing director at Luoxin pharmaceutical (Shanghai) Co., Ltd since August 2018 . Prior to that, she was purchasing director in Nanjing Sanhome pharmaceutical Co., Ltd with wide range coverage from infrastructure, equipment, material , outsourcing service to commercialization. Before that, she was Asia purchasing head at Futuris Automotive Interior Co., Ltd with rich experience in whole purchasing team management and cost control.
Ms. Yue obtained her bachelor’s degree of industry from Nanchang Institute of Aeronautical Technology in 1993.
Rebecca Zhang was the Head of Regulatory Affairs at I-Mab Biopharma Ltd. Co. prior to coming to CANbridge, where she focused on Oncology and Immunology. Under her leadership, I-Mab successfully achieved 6 IND applications and approvals in China and 1 IND approval in the US; she and her team also provided end-to-end regulatory strategy support for all pipeline products, from discovery to the post-approval stage. Before joining I-Mab, she had more than 20 years’ regulatory affairs experience in several multi-national corporations, including GSK, Sanofi, AZ, and Johnson & Johnson, where she led a large RA team to support business in China. Zhang started her career as a physician in the China-Japan Friendship Hospital.
Rebecca Zhang holds a Bachelor of Science from the Beijing Traditional Chinese Medicine University.
Dr. James Qun Xue, Ph.D., M.B.A., has served as Chairman of the Board,Director and Chief Executive Officer since the inception of our Company in January 2018 and was re-designated as an executive Director on June 21, 2021. Dr. Xue is the founder of our Company and has been actively involved in the business, strategy and operational management of our Group since its establishment. Dr. Xue has over 22 years of experience in medical and pharmaceutical companies. Dr.Xue began his career as a scientist at Kosan Biosciences, Inc. from May 1998 to August 2000,where he dedicated himself to research in bioengineering. In 2002, Dr. Xue joined GenzymeCorporation, where he served in various positions with increasing responsibilities including,among others, the general manager of Genzyme China and senior director of business excellence, and accumulated extensive management experience there until 2011. Since June 2012, Dr. Xue has served as venture partner at Tullis Health Investors where he was principally responsible for providing advice on portfolio company investments and maintaining and enhancing company’s brand and market position.
Dr. Xue is deputy director general of the China Alliance for Rare Disease (中國罕見病聯盟), deputy director of the Shanghai Foundation for Rare Disease. He is the vice chair of the R&D committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA)，member of the Special Committee on Drugs for Rare Diseases，Chinese Pharmaceutical Association（CPA） and a member of the Leadership Council of the Joint Institute of Peking University Health Science Center and University of Michigan Medical School . Dr. Xue has also been a member of BayHelix Group, a non-profit organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry and a mentor of the Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines.
Dr. Xue obtained his Bachelor of Science degree in pharmaceutical chemistry from Peking University School of Pharmacy in July 1992. He further obtained his Ph.D. in bioorganic chemistry from Brown University in April 1997. In addition, Dr. Xue received his postdoctoral degree in pharmaceutical chemistry and biochemistry from University of California in April 1998 and his Master of Business Administration from Darden School of Business, University of Virginia in May 2002.
Dr. Gao joined CANbridge as the Advisory Board member for the gene therapy initiative collaboration with the University of Massachusetts Medical School in June 2020.
Dr. Gao is an internationally recognized gene therapy researcher who has played a key role in the discovery and characterization of new AAV serotypes. He is currently President of the American Society of Gene and Cell Therapy, Director of Horae Gene Therapy Center and Viral Vector Core, Co-director of Li Weibo Institute for Rare Diseases Research, and the Penelope Booth Rockwell Professor at UMass Medical School. He has authored 250+ research papers, six book chapters, four edited books, and holds 131 patents, with 221 more pending. Dr. Gao was ranked #4 of Top 20 Translational Researchers from 2013 to 2017 by Nature Biotechnology. He is also the co-founder of Voyager Therapeutics and Aspa Therapeutics.
Dr. Mark Goldberg has been a member of our advisory board since 2013 and served as our Acting Chief Medical Officer from 2015 to 2018, bringing over 30 years of clinical and industry experience as a seasoned oncologist, hematologist and corporate medical/regulatory strategist. Dr. Goldberg is a medical oncologist and hematologist on the faculty of Brigham & Women’s Hospital and Harvard Medical School, a veteran biotech executive, and long-time American Cancer Society (ACS) and ACS Cancer Action Network (CAN) volunteer. He is the past-chair of the Eastern New England Area Board of the American Cancer Society and currently serves as a member of its national board of directors. Dr. Goldberg previously served on the executive management team of Synageva Biopharma from 2011 to 2014, including as Executive Vice President, Medical and Regulatory Strategy. Prior to joining Synageva, Dr. Goldberg served in various management capacities of increasing responsibility at Genzyme Corporation from 1996 to 2011, most recently as Senior Vice President, Clinical Development and Global Therapeutic Head, Oncology, Genetic Health, and as Chairman of Genzyme’s Early Product Review Board。
Dr. James Qun Xue, Ph.D., M.B.A., has served as Chairman of the Board,Director and Chief Executive Officer since the inception of our Company in January 2018 and was re-designated as an executive Director on June 21, 2021. Dr. Xue is the founder of our Company and has been actively involved in the business, strategy and operational management of our Group since its establishment. Dr. Xue has over 22 years of experience in medical and pharmaceutical companies. Dr.Xue began his career as a scientist at Kosan Biosciences, Inc. from May 1998 to August 2000,where he dedicated himself to research in bioengineering. In 2002, Dr. Xue joined GenzymeCorporation, where he served in various positions with increasing responsibilities including,among others, the general manager of Genzyme China and senior director of business excellence, and accumulated extensive management experience there until 2011. Since June 2012, Dr. Xue has served as venture partner at Tullis Health Investors where he was principally responsible for providing advice on portfolio company investments and maintaining and enhancing company’s brand and market position.
Dr. Xue is deputy director general of the China Alliance for Rare Disease (中國罕見病聯盟), deputy director of the Shanghai Foundation for Rare Disease. He is the vice chair of the R&D committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA)，member of the Special Committee on Drugs for Rare Diseases，Chinese Pharmaceutical Association（CPA） and a member of the Leadership Council of the Joint Institute of Peking University Health Science Center and University of Michigan Medical School . Dr. Xue has also been a member of BayHelix Group, a non-profit organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry and a mentor of the Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines.
Dr. Xue obtained his Bachelor of Science degree in pharmaceutical chemistry from Peking University School of Pharmacy in July 1992. He further obtained his Ph.D. in bioorganic chemistry from Brown University in April 1997. In addition, Dr. Xue received his postdoctoral degree in pharmaceutical chemistry and biochemistry from University of California in April 1998 and his Master of Business Administration from Darden School of Business, University of Virginia in May 2002.
Dr. Hu has a rich background in healthcare investment, operations and administrative management and is a seasoned entrepreneur, having founded Beijing Amcare Women’s & Children’s Hospital Co. in 2004, where she also served as Director, Chairman of the Board and General Manager. Currently, she is the Chairman of the Board and General Manager of Beijing Amcare Medical Management Co., Ltd.; the Chairman of the Board of Beijing Meizhong Airui Tumor Hospital Co., Ltd.; the independent Director of Beijing Yida Shidai Technology Development Co., Ltd. and the Executive Director and General Manager of Beijing Xuanhe Yazhi Management Consulting Co., Ltd. Dr. Hu is a member of 12th and 13th Beijing Municipal Committee of the Chinese People’s Political Consultative Conference, a position she has held since 2013. From 2002-2004, she was an Investment Manager at JP Morgan Chase Bank.
Dr. Hu has a Ph.D. in medical sciences from Medical College of Ohio and a Master’s Degree in Business Administration from The University of Michigan, in Ann Arbor, Michigan. She has a Bachelor’s Degree in medicine from Peking University, in Beijing, China.
Dr. Li, aged 32, has been serving as the senior investment manager of WuXi AppTec Singapore Pte. Ltd., a subsidiary of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司), a company listed on Shanghai Stock Exchange (stock code: 603259) and the Main Board of the Stock Exchange of Hong Kong Limited (the “Stock Exchange”) (stock code: 2359), and is primarily responsible for direct investment and portfolio management in healthcare industry, since April 2021. Dr. Li is currently a nonexecutive director of Hua Medicine, a company listed on the Main Board of the Stock Exchange (stock code: 2552). He was a consultant of Bain & Company, a management consulting firm, and was primarily responsible for providing strategy and conducting commercial due diligence for healthcare players, from April 2019 to December 2020. He was a cofounder and the chief executive officer of HAIKUI Regenerative Medicine, and was primarily responsible for research and development in cartilage and dermal implantation technologies, from August 2016 to January 2019.
Dr. Li received his bachelor’s degree in engineering from Imperial College London in the United Kingdom in June 2014. He obtained a PhD degree in Tissue Engineering from University of Oxford in the United Kingdom in September 2018.
Mr. James Arthur Geraghty, was appointed as an independent non-executive Director on July 18, 2018. Mr. Geraghty has served as an independent non-executive director of CANbridge Life Sciences, our wholly-owned subsidiary, since May 2017. Mr. Geraghty is responsible for supervising and providing independent judgment to our Board.
Mr. Geraghty has approximately 30 years’ management experience in business development, strategy and operations. Mr. Geraghty was an entrepreneur in residence of Third Rock Ventures from May 2013 to December 2016, where he was responsible for company formation and governance. Prior to this, Mr. Geraghty served as the senior vice president responsible for strategy and business development at Sanofi S.A. between April 2011 and December 2012. Mr. Geraghty worked with Genzyme Corporation from 1992 to 2011, with his last position being the senior vice president responsible for international development. From 1993 to 2007, Mr. Geraghty served as the chairman of board and the chief executive officer for Genzyme Transgenics Corporation. Prior to that, Mr. Geraghty started his career at Bain Capital, responsible for healthcare strategy consulting. Mr. Geraghty has been the chairman of the board of Orchard Therapeutics (NASDAQ: ORTX) and Pieris Pharmaceuticals (NASDAQ:PIRS) since May 2018 and since November 2017, respectively. Mr. Geraghty has also served as an independent non-employee Director of Fulcrum Therapeutics (NASDAQ: FULC) since October 2016, Voyager Therapeutics (NASDAQ: VYGR) since January 2014 and Idera Pharmaceuticals (NASDAQ: IDRA) since July 2013, respectively.
Mr. Geraghty received his bachelor’s degree in psychology from Georgetown University and received his Juris Doctor degree from Yale University Law School in May 1980.
Dr. Richard James Gregory, Ph.D., was appointed as an independent non-executive Director in April 2020. Dr. Gregory is responsible for supervising and providing independent judgment to our Board.
Dr. Gregory has over 30 years’ experience in research and development. Dr. Gregory has served as an independent non-employee director of Homology Medicines (NASDAQ: FIXX) since 2015 and is currently an independent director of ProMIS Neurosciences (TSX: PMN). Dr. Gregory was the executive vice president and the chief scientific officer of ImmunoGen Inc. from January 2015 to August 2019. Prior to that, since February 1989, Dr. Gregory had spent 25 years at Genzyme Corporation (NASDAQ: GENZ) in roles of increasing responsibility, including Vice President and senior Vice President, with his last position being the Head of Research and Development for Genzyme Sanofi. In early 1990s, he also worked with Canji, Inc., focusing on the field of molecular biology. In 1989, Dr. Gregory served as a postdoctoral fellow of the Worcester Foundation for Experimental Biology.
Dr. Gregory received his bachelor’s degree in Science in Biochemistry from Virginia Polytechnic Institute and State University in June 1980 and his Ph.D. degree from University of Massachusetts Amherst in January 1986. Dr. Gregory has been a fellow of the American Institute for Medical and Biological Engineering since February 2010.
Mr. Peng Kuan Chan (陳炳鈞), was appointed as an independent nonexecutive Director of the Company on June 11, 2021. Mr. Chan is responsible for supervising and providing independent judgment to our Board.
Mr. Chan has over 25 years of experience in corporate financing, investment banking, initial public offering, mergers and acquisitions as well as financial management. From October 2017 to May 2019, Mr. Chan was the chief financial officer of Elegance Optical International Holdings Ltd (HKEX: 0907), where he was responsible for corporate finance and financial management. Prior to this, from January 2012 to September 2017, Mr. Chan served as the chief operating officer of CITIC Merchant Co., Limited, responsible for formulating business strategies and executing business plans of the company. Between January 2011 and November 2011, Mr. Chan served as Head of Asia CIG and Cleantech of Piper Jaffray Asia Limited. Mr. Chan served as the managing director of corporate finance – Great China coverage department, and an executive director of corporate finance department of BNP Paribas Capital (Asia Pacific) Limited from July 2006 to January 2011 and from March 2005 to June 2006, respectively. Between August 2000 and December 2004, Mr. Chan served as an executive director of Sanyuan Group Limited (三元集團有限公司), a company delisted from the Stock Exchange in December 2009 (stock code: 140) which principally engaged in property investment and bio-pharmaceuticals, with the mission of restructuring its business activities and materialising its debt restructing plan. He served as an executive director of BNP Prime Peregrine Capital Limited from May 1994 to August 2000.
Mr. Chan received his bachelor’s degree in commerce from University of Canterbury in May 1989 and received his master’s degree in applied finance from Macquarie University in November 1998. He has been a Chartered Accountant of Chartered Accountants Australia and New Zealand since November 1992. He has been a Certified Public Accountant of the Hong Kong Institute of Certified Public Accountants (“HKICPA”) since July 1993.
